Novo Nordisk to Present Semaglutide Clinical Trial Data at ADA's 84th Scientific Sessions

Novo Nordisk, based in Bagsværd, Denmark, is set to present 34 abstracts at the upcoming 84th Scientific Sessions of the American Diabetes Association (ADA), taking place from June 21-24, 2024, in Orlando, USA. The presentations span a broad spectrum of their pharmaceutical portfolio, highlighting key research findings on the efficacy and safety of semaglutide and other treatments.

Among the notable studies to be showcased are three landmark trials involving semaglutide. These trials evaluate the additional benefits of semaglutide, focusing on kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (FLOW, semaglutide 1.0 mg) and the impact on cardiovascular and glucose-related endpoints in patients with obesity and cardiovascular disease, with and without diabetes (SELECT and STEP HFpEF, semaglutide 2.4 mg).

Stephen Gough, Senior Vice President and Global Chief Medical Officer at Novo Nordisk, emphasized the importance of addressing the interconnected nature of cardiometabolic conditions such as cardiovascular disease, chronic kidney disease, obesity, and type 2 diabetes. He noted that the data being presented at the ADA sessions reflect Novo Nordisk’s commitment to developing comprehensive treatments for these interrelated diseases.

The conference will feature several dedicated scientific sessions to present these findings. The FLOW trial, the first kidney outcome study involving a GLP1 receptor agonist used once weekly (semaglutide 1.0 mg), will be presented on June 24. The SELECT trial, which examines glycemic control, inflammation, and heart failure, will be showcased on June 22. Additionally, the STEP-HFpEF and STEP-HFpEF-DM trials, which explore the potential of targeting obesity to treat heart failure, will be discussed on June 23.

In addition to the dedicated scientific sessions, Novo Nordisk will present various poster and oral presentations on their diabetes and obesity treatments. These include studies on the real-world impact of once-weekly injectable semaglutide (Ozempic®), the efficacy of oral semaglutide (Rybelsus®) in different populations, and the benefits of once-weekly insulin icodec.

The abstracts accepted for presentation cover a range of topics. For example, Ozempic® will be evaluated for its effectiveness in managing type 2 diabetes, while Rybelsus® will be examined for its efficacy in Chinese patients and its impact during Ramadan. Other studies will delve into the benefits of CagriSema, a combination therapy, and once-weekly insulin icodec, highlighting its advantages over daily basal insulin.

Novo Nordisk will also present research on the general management of diabetes and obesity. Studies will explore the persistence and adherence to GLP-1 receptor agonists, the impact of newer GLP-1 RAs on HbA1c levels, and the clinical outcomes of weight management strategies.

Ozempic® (semaglutide) is approved for use in varying doses to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events. Rybelsus®, an oral form of semaglutide, offers similar benefits but in a daily format. Wegovy® (semaglutide 2.4 mg) is approved for weight management in patients with obesity or overweight, combined with a reduced-calorie diet and increased physical activity.

Novo Nordisk, founded in 1923, is a leading healthcare company focused on defeating serious chronic diseases. With approximately 66,000 employees worldwide, the company markets its products in around 170 countries. Their significant presence at the ADA Scientific Sessions underscores their commitment to advancing treatments for diabetes and related conditions.